Crossmark

The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy

Published Online: 2023-01-27

Published Print: 2023-03

Authors

Hines, Jacobi B.

Kacew, Alec J.

Sweis, Randy F. https://orcid.org/0000-0002-0497-9637
License Information

Text and Data Mining valid from 2023-01-27

Version of Record valid from 2023-01-27
More Information

Article History

Accepted: 7 November 2022

First Online: 27 January 2023

Declarations

:

: This article does not contain any studies with human or animal subjects performed by any of the authors.

: JBH and AJK have nothing to disclose. Randy F. Sweis reports research grants from Astellas, AstraZeneca, Bristol Myers Squibb (BMS), CytomX, Eisai, Eli Lilly, Genentech/Roche, Immunocore, Moderna, Mirati, Novartis, Pfizer, and QED Therapeutics; consulting/advisory fees from Astellas, AstraZeneca, BMS, Eisai, Janssen, Mirati, Pfizer, and Seattle Genetics; and pending patent for Neoantigens in Cancer.

Document is current